Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma
GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for the...
Business Wire·17h ago
More News
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1d ago
Top Analyst Reports for Oracle, Toyota & Morgan Stanley
Oracle gains from cloud momentum and AI contracts, Toyota drives hybrid and hydrogen growth, while Morgan Stanley thrives on IB strength.
Zacks·2d ago
GSK (GSK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2d ago
Here's Why GSK (GSK) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·3d ago
Here's Why GSK (GSK) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·4d ago
Will Positive Regulatory Updates Further Boost INCY Stock?
Incyte's strong 2025 performance is fueled by Jakafi's sustained growth and label expansion of Opzelura.
Zacks·4d ago
Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings?
MIRM's Livmarli remains its dominant growth engine and is expected to have boosted its top line in the third quarter.
Zacks·10d ago
Why GSK (GSK) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·15d ago
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy
Gilead's settlement on Biktarvy patents delays generic entry until 2036, boosting investor confidence.